anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The treatment in the intervention arm consists of the Friendship Bench Plus Intervention (FB+) which combines six sessions of problem-solving therapy for depression delivered by trained Lay Health Workers and nurse-led prescription of antidepressants. The nurse will begin on the day of the first FB counselling session with 20mg Fluoxetine or 50mg Sertraline if breastfeeding. The nurse will then dispense the antidepressants for two weeks. As the study population comprises patients with more severe forms of depression, the investigators don't expect a relevant response to this starting dose. Therefore, after two weeks, which corresponds to the third FB counselling session, the nurse will increase to 40mg Fluoxetine or 100mg Sertraline if breastfeeding.If patients show \<30% improvement in PHQ-9 as compared to baseline on the sixth study vist, Fluoxetine will be increased to 60mg and Setraline to 150mg.
The Hispanic population of the United States is the second largest racial or ethnic group, comprising 18.7% of the population. However, this population is incredibly heterogeneous differing in genetic traits, cultural upbringing, educational backgrounds, and financial status. The impact of this heterogeneity on the prevalence and outcomes of renal disease and kidney transplantation is understudied compared with non-Hispanic White and Black populations. What is known appears to be underrecognized. This review aims to critically assess current medical literature on Hispanic individuals, focusing on etiological factors, disease progression, and outcomes related to CKD and kidney transplantation. By doing so, we aim to underscore key areas for further in-depth investigation.
The invention belongs to the field of traditional Chinese medicine and particularly discloses a traditional Chinese medicine combination for treating accumulated toxin decaying type bedsores. The combination is composed of internal medicine and medicine for external use. The internal medicine is prepared from, by weight, 15-35 parts of astragalus, 8-13 parts of angelica, 8-20 parts of radix rehmanniae, 9-15 parts of atractylodes macrocephala koidz, 10-30 parts of willow-leaved smartweed, 5-10 parts of Chinese dates, 15-30 parts of centella asiatica and 6-11 parts of licorice roots. The medicine for external use is prepared from, by weight, 15-30 parts of artemisia anomala, 15-45 parts of galium aparine, 10-20 parts of ranunculus ternatus, 8-13 parts of verbena and 5-15 parts of radix angelicae dahuricae. The internal medicine has the functions of tonifying qi and yin, clearing away heat and toxic materials, inducing diuresis and reducing edema. The medicine for external used has the function of eliminating necrotic tissue and promoting granulation. Mainly the internal medicine and the medicine for external use are matched and used for the three main pathological links of decay, stagnation and deficiency, qi and blood are regulated, and finally the purposes of promoting granulation and making flesh are achieved.
Host-directed therapy (HDT) is a new adjuvant strategy that interfere with host cell factors that are required by a pathogen for replication or persistence. In this study, we assessed the effect of dehydrozaluzanin C-derivative (DHZD), a modified compound from dehydrozaluzanin C (DHZC), as a potential HDT agent for severe infection. LPS-induced septic mouse model and Carbapenem resistant Klebsiella pneumoniae (CRKP) infection mouse model was used for testing in vivo. RAW264.7 cells, mouse primary macrophages, and DCs were used for in vitro experiments. Dexamethasone (DXM) was used as a positive control agent. DHZD ameliorated tissue damage (lung, kidney, and liver) and excessive inflammatory response induced by LPS or CRKP infection in mice. Also, DHZD improved the hypothermic symptoms of acute peritonitis induced by CRKP, inhibited heat-killed CRKP (HK-CRKP)-induced inflammatory response in macrophages, and upregulated the proportions of phagocytic cell types in lungs. In vitro data suggested that DHZD decreases LPS-stimulated expression of IL-6, TNF-α and MCP-1 via PI3K/Akt/p70S6K signaling pathway in macrophages. Interestingly, the combined treatment group of DXM and DHZD had a higher survival rate and lower level of IL-6 than those of the DXM-treated group; the combination of DHZD and DXM played a synergistic role in decreasing IL-6 secretion in sera. Moreover, the phagocytic receptor CD36 was increased by DHZD in macrophages, which was accompanied by increased bacterial phagocytosis in a clathrin- and actin-dependent manner. This data suggests that DHZD may be a potential drug candidate for treating bacterial infections.
Dental fear and phobia are widespread worldwide, with local anesthesia being one of the procedures that patients fear the most. To alleviate the pain associated with needle insertion and the need for repeat procedures, various complementary therapies have been introduced. However, to date, there is no established protocol for this intervention. The objective of this study is to assess whether pre-anesthetic photobiomodulation (PBM) can effectively reduce needle puncture pain and enhance the efficiency of local anesthesia. In this double-blind randomized controlled trial, 50 participants were included. The control group underwent the standard anesthetic procedure, while the experimental group received the application of an infrared laser (100mW at 808nm, 8J at a single point) immediately before anesthesia, at the site of the intended needle puncture. Both groups underwent the same anesthetic procedure, administered by the same operator. The outcome evaluator and the patient were blind to the FBM application. The primary outcome of the study focused on pain experienced at the time of needle insertion, assessed using the Visual Analogue Scale (VAS) during the needle's introduction. Secondary outcomes encompassed anxiety levels, measured using the Beck questionnaire, anesthetic onset time determined through the electric pulp test, the number of anesthetics required for the procedure, and the necessity for supplementary anesthesia. Categorical variables will be presented as absolute and relative frequencies and compared using the Pearson chi-squared test, likelihood ratio test, or Fisher's exact test. Quantitative variables will be assessed for normality using the Kolmogorov-Smirnov test. Outcome variables will be presented as mean and standard deviation or median and interquartile range (IQR) and compared using the Student's t-test or Mann-Whitney test. Variables measured under multiple conditions will be compared using analysis of variance for repeated measures. A significance level of P \< 0.05 will be considered statistically significant.
A cochlear implant (CI) is a device that restores the sense of hearing in people with severe to profound hearing loss. This implant consists of two parts: The first is an internal component, which is surgically implanted under the skin behind the ear and connected to electrodes that are inserted inside the cochlea. The second is an external component that sits behind the ear and consists of a speech processor, a microphone, and a battery compartment. However, complications following device implantation may occur; these complications include flap erosion, local infections, general infections that may lead to meningitis, wound healing disorders, electrode insertion, device migration, and facial nerve injury (1,2). The incidence of infectious complications is quite uncommon, but potentially serious complication of CI surgery occurs at a rate of 1.7% to 4.1% (3-5). CI infection may be managed with conservative treatment modalities; however, persistent infection often ends in implant removal or implant replacement (6).

The body responds to inflammation and stress, including trauma, surgery, or sepsis, by elevating the neutrophil count and by reducing the lymphocyte count (7). Neutrophil/ lymphocyte ratio (NLR) is an indicator of poor prognostic factor in inflammation and in some diseases, such as obstructive sleep apnea syndrome, ischemic cardiac diseases, several types of cancer, and Bell's palsy (8-11). Platelet/ lymphocyte ratio (PLR) is also associated with inflammation and poor prognosis in patients with different types of cancer (12,13). Platelets release proinflammatory mediators, such as chemokines and cytokines (14). NLR and PLR can be calculated from complete blood count (CBC), a cheap and simple means of obtaining information regarding inflammation. During an inflammatory reaction, the amount of leukocytes in the circulation changes (9,15).

The relationship of preoperative NLR and PLR with CI infection has not yet been investigated and it is being aimed to show the predictive value of NLR and PLR in patients who developed implant infection after CI placement. First outcome is to compare whether there is a difference between NLR in patients with and without implant infection in patients with cochlear implant implantation. Secondary outcome is to determine which NLR is susceptible to infection if there is a difference between NLR between patients with and without implant infection.
PURPOSE: To provide a new acidic functional polyhydroharman-type derivative useful as a thromboxane synthase inhibitor. CONSTITUTION: The inhibitor is composed of a compound of the formula ((n) is 4-8; B5 , B6 , B7 and B8 are each C or N; R1 is a residue at 5, 6, 7 or 8-position; R2 is a residue at 1, 3 or 4-position; La is a bivalent bonding group; A is an acidic group), e.g. 5,6,7,8-tetrahydro-β-carboline-1-hexanoic acid ethyl ester. The compound can be produced e.g. by reacting 5,6,7,8-tetrahydro-/β-calboline with 6-iodohexanoic acid ethyl ester in the presence of NaH in anhydrous DMF. The agent is useful for the prophylaxis and treatment of phlebothrombosis, pulmonary embolism, arterial thrombosis, myocardial ischemia, myocardial infarction, cerebral thrombosis, systemic hypercoagulation symptom and local hypercoagulation symptom complicating in angioplasty and coronary bypassing operation and thrombosis and embolism such as systemic tissue damage relating to inflammation process.
BACKGROUND Hemoptysis due to airway hemorrhage is treated with hemostatic agents, bronchial artery embolization (BAE), or surgical resection. We present the case of a 65-year-old man with refractory hemoptysis associated with chronic progressive pulmonary aspergillosis (CPPA) who failed to respond to combined endobronchial occlusion (EBO) with endobronchial Watanabe spigot (EWS) and BAE. CASE REPORT A 63-year-old man was diagnosed with CPPA in the right upper lung and presented to our hospital 2 years later for hemoptysis at age 65. He developed severe hemoptysis during an outpatient visit, and was urgently admitted, intubated, and ventilated to prevent choking on blood clots. Chest computed tomography showed a large mass in the apical portion of the right lung, constituting apical pleural thickening and an encapsulated pleural effusion, and dilatation in the bronchial artery supplying the right upper lung lobe. Bronchoscopy revealed the right upper lobe B1-B3 as the bleeding source. The patient had recurrent hemoptysis that was not controlled by BAE or 6 EBO+EWS procedures, and he ultimately died of hypoxemia.In the literature review, EBO+EWS can effectively control hemoptysis in appropriate cases, without the need for BAE or surgical lung resection. It is less invasive, is associated with fewer adverse events than BAE or surgery, and can achieve temporary hemostasis for severe hemoptysis. CONCLUSIONS BAE and EBO+EWS were ineffective in controlling recurrent hemoptysis caused by CPPA in this case. However, a multidisciplinary approach such as attempting hemostasis with combined EBO+EWS and BAE may be a viable treatment option in severe cases of hemoptysis.
This group will undergo neurofeedback intervention in the fMRI scanner in weeks 1,5 and 12. They will also undergo physical exercise training on WiiFit device once a week after the first month till the end of the study at 12 weeks.
BACKGROUND: Studies have shown that the chronic use of cannabis is associated with a decrease in blood pressure. Our previous studies prove that activating the cannabinoid type 2 (CB2) receptor in the brain can effectively reduce blood pressure in spontaneously hypertensive rats; however, the exact mechanism has not been clarified. The objective of this study is to demonstrate that activation of microglial CB2 receptors can effectively reduce the levels of TNF-α, IL-1β, and IL-6 in the paraventricular nucleus (PVN) through inhibiting aerobic glycolysis, thereby relieving hypertension.
METHODS: AngiotensinII (AngII) was administered to BV2 cells and C57 mice to induce hypertension and the release of proinflammatory cytokines. The mRNA and protein expression of the CB2 receptor, TNF-α, IL-1β, IL-6, and the PFK and LDHa enzymes were detected using RT-qPCR and Western blotting. The Seahorse XF Energy Metabolism Analyzer was used to measure the oxidative phosphorylation and aerobic glycolysis metabolic pathways in BV2 cells. The long-term effects of injecting JWH133, a selective CB2 receptor agonist, intraperitoneally on blood pressure were ascertained. ELISA was used to measure norepinephrine and lactic acid levels while immunofluorescence labeling was used to locate the CB2 receptor and c-Fos. By injecting pAAV-F4/80-GFP-mir30shRNA (AAV2-r-CB2shRNA) into the lateral cerebral ventricle, the CB2 receptor in microglia was specifically knocked down.
RESULTS: Activation of CB2 receptors by the agonist JWH133 suppressed TNF-α, IL-1β, and IL-6 by inhibiting PFK and LDHa enzymes involved in glycolysis, as well as lactic acid accumulation, along with a reduction in glycoPER levels (marks of aerobic glycolysis) in AngII-treated BV2 cells. In AngII-treated mice, the administration of JWH133 specifically activated CB2 receptors on microglia, resulting in decreased expression levels of PFK, LDHa, TNF-α, IL-1β, and IL-6, subsequently leading to a decrease in c-Fos protein expression within PVN neurons as well as reduced norepinephrine levels in plasma, ultimately contributing to blood pressure reduction.
CONCLUSION: The results suggest that activation of the microglia CB2 receptor decreases the neuroinflammation to relieve hypertension; the underlying mechanism is related to inhibiting aerobic glycolysis of microglia.
Methods for providing online health monitoring (16) and accumulating data from patients worldwide and accompanying apparatus for using the same, are disclosed. Such monitoring is particularly useful for both diagnosing and prescribing preventive medical treatment, and is particularly suited for the field of cardiovascular health care. Preferred methods and devices include using a sensitive acoustic device such as an electret, to analyze a patient's cardiovascular functions from a location such as a public computer kiosk, a doctor's office or a patient's home computer. The data may be downloaded from an acoustic device to a central database located, for example on the Internet. The data may be retrieved by the patient, or upon instructions from the patient, may be transferred to or accessed by doctors for purposes of diagnosis, monitoring and treatment. Data may include patient demographics. This data is accessible by researchers who will have medical statistics on a wide variety of patients from various age groups and medical histories.
PROBLEM TO BE SOLVED: To obtain a granular agent having the high uniformity of the content of a pharmacologically active material, excellent fluidity and low splashing property by spraying the low melting pharmacologically active material which is hardly subjected to a chemical change by heat in a thermally melted state to powder to be granulated while allowing this powder to flow, then spraying a binder liquid and granulating the powder. SOLUTION: While the powder to be granulated is allowed to flow, the low melting pharmacologically active material which is hardly subjected to the chemical change by heat is sprayed in the thermally melted state to this powder. The binder liquid is then sprayed thereto and the powder is granulated. The low melting pharmacologicallly active material which is hardly subjected to the chemicla change by heat signifies a pharmacologically active material which does not induce the chemical change at a temp. below 100 deg.C and its m.p. is 30 to 100 deg.C. Such material includes, for example, idebenone, etc. Powders contg. milk sugar and corn starch or powders contg., crystalline cellulose are used for the powder to be granulated. Liquid binder contg. corn starch is used.
Procedure:The surgical site was anesthetized with articaine-epinephrine. After buccal intracervicular incision on vestibular aspects of two teeth surrounding the intrabony defect, a beveled vertical releasing incision was made in the buccal gingiva of the tooth affected by the intrabony defect, on the opposite site to the intrabony defect and extended beyond the mucogingival line to provide access to the intrabony defect. A buccal full thickness mucoperiosteal flap extending from the vertical incision to the defect-associated papilla and neigboring tooth was elevated. Interdental tunnel under the papillary tissue was elevated to the lingual bone crest. Granulation tissue and calculus from the inner aspect of interdental papilla was removed.24%EDTA was applied on the exposed root surface, than rinsed and EMD and bone substitute was applied. Vertical incision was closed with simple single sutures, whereas due to modification of the original technique additional sling suture was applied.
BACKGROUND: Asia accounts for more than half of the world's population and carries a substantial proportion of the global burden of blindness and vision impairment. Characterising this burden, as well as its causes and determinants, could help with devising targeted interventions for reducing the occurrence of blindness and visual impairment.
METHODS: Using the Global Burden of Disease Study 2019 database, we retrieved data on the number of disability-adjusted life years (DALYs); crude and age-standardised rates; and the prevalence (with 95% uncertainty intervals (95%UIs)) of blindness and vision loss due to six causes (age-related macular degeneration, cataracts, glaucoma, near-vision impairment, refractive error, and other vision loss) for Asian countries for the period between 1990 and 2019. We defined DALYs as the sum of the years lost due to disability and years of life lost, and calculated age-standardised figures for the number of DALYs and prevalence by adjusting for population size and age structure. We then evaluated the time trend of the disease burden and conducted subgroup analyses by gender, age, geographic locations, and socio-demographic index (SDI).
RESULTS: In 2019, the DALYs and prevalence of blindness and vision loss had risen by 90.1% and 116% compared with 1990, reaching 15.84 million DALYs (95% UI = 15.83, 15.85) and 506.71 million cases (95% UI = 506.68, 506.74). Meanwhile, the age-standardised rate of DALYs decreased from 1990 to 2019. Cataracts, refractive error, and near vision impairment were the three most common causes. South Asia had the heaviest regional disease burden (age-standardised rate of DALYs = 517 per 100 000 population; 95% UI = 512, 521). Moreover, the burden due to cataracts ranked high in most Asian populations. Being a woman; being older; and having a lower national SDI were factors associated with a greater vision loss burden.
CONCLUSIONS: The burden due to vision loss remains high in Asian populations. Cataracts, refractive error, and near vision loss were the primary causes of blindness and vision loss. Greater investment in ocular disease prevention and care by countries with lower socioeconomic status is needed, as well as specific strategies targeting cataract management, women and the elderly.
Individuals with quadriplegia will be recruited for participation in three sessions of intermittent theta burst stimulation (iTBS), each consisting of sham iTBS applied to the hotspot of the target muscle and active iTBS; sham iTBS always be will administered first to minimize the potential for carry over effects. Sessions will be separated by at least 3 days to minimize the potential for carry over effects. Before and 10, 20 and 30 minutes after each iTBS session, motor evoked potentials (MEPs) will be recorded in order to quantify changes in corticomotor excitability.
The invention discloses a method for healing diabrosis and stopping bleeding. The method utilizes a formula comprising 250ml of a water chestnut juice, 250ml of honey and 10g of radix tinosporae powder. The method comprises heating to boil the water chestnut juice, cooling the water chestnut juice to a temperature of 60 DEG C, adding honey and radix tinosporae powder into the water chestnut juice, stirring the mixture and cooling the mixture. 20ml of the mixture can be taken orally once, 4-6 times every day. The method solves the problem that the existing method for treating digestive system diseases caused by injuries, diseases, pain and hemorrhage utilizes injections and oral drugs, has a slow curing rate and needs a high cost. The method is very suitable for diabrosis healing and bleeding stopping.
Eligible, consented children will be prepared for general anaesthesia in the usual way. After start of anesthesia (="induction"), adequate face-mask ventilation will be established. The sealed envelope for randomisation will then be opened. Standard anesthesia will be continued, either using sevoflurane or propofol (anesthesia depth controlled by Narcotrend, to measure anesthesia depth using processed EEG waves). They will receive additional non-invasive monitoring for this study, such as transcutaneous measurement of tcCO2 and O2, NIRS, and thoracic electrical impedance tomography (EIT, PulmoVista® 500, Draeger, Luebeck, Germany) All patients will receive neuromuscular blockade medication of 2 x ED95 (standard intubation dose) to facilitate airway management and total intravenous anesthesia will be installed (continuous application of i.v. anesthesia medication). Up to two minutes of bag-mask ventilation with 100% oxygen and flow rates of 6-8L/min will be applied until an expired oxygen concentration of \>90% is reached, as well as an SpO2 of 100% and an transcutaneous CO2 of 30-40mmHg.

For the study intervention, the bag-mask ventilation will be discontinued, and the child will be left apnoeic (the same happens always during intubation) until the saturation drops to 95%, which is still a low normal value. According randomization, any of the two study intervention s will be applied (THRIVE therapy with 100% O2 2l/kg/min, THRIVE therapy with 100% O2 4l/kg/min, all via nasal cannulas) while simultaneously guaranteeing an open airway by using Esmarch's procedure (jaw thrust) and an oral airway (Guedel tube). ECG, pulse-oximetry, blood pressure, Narcotrend, NIRS, thoracic EIT, PtcO2, PtcCO2 will be measured continuously over the study period. The time until desaturation from SpO2 100% to SpO2 95% will be also measured. A chest ultrasound at the end of the intervention will prove that no pneumothorax developed during the procedure. The study intervention will end at the time the saturation reaches SpO2 95% or when any other break-up criteria are reached. Bag mask ventilation will then be re-applied until SpO2 reaches again 100% and the patient will be treated according to the attending anaesthesiologist to ultimately establish a patent airway. Break-up criteria during apnoea are: SpO2 below 95%, transcutaneous CO2 above 70 mmHg, or time of apnoea \>10 minutes. Drop of NIRS \> 30% from baseline. A postmedication interview will be performed before PACU discharge.